David Haddock Increases Stake in MD with 51,000-Share Purchase

David Haddock, Executive Vice President at MD, recently purchased 51,000 shares of the company on June 22, 2026. This insider transaction comes as part of a series of recent insider activities at MD. Shares of MD traded near $23.86 on Thursday.

Insider Buying and Selling at Pediatrix Medical Group, Inc.

David Haddock, serving as EVP, GC & Corporate Secretary, wasn't the only insider active recently. On the same day, he also acquired an additional 20,036 shares. Meanwhile, Mary Ann Moore, EVP and Chief Administrative Officer, was involved in both buying and selling 18,407 shares on June 9, 2026. Additionally, CEO Mark Ordan executed similar transactions, buying and selling 97,174 shares on June 2, 2026.

Other Institutional Activity in MD

Several institutional investors have also been making moves in MD. BlackRock, Inc. increased its holdings by 12,103 shares, bringing its total to 13,574,373 shares valued at approximately $290.36 million. Vanguard Portfolio Management LLC opened a new position with 6,154,126 shares valued at $131.64 million. American Century Companies Inc. added 227,231 shares, raising its stake by 6.1% to 3,925,366 shares worth about $83.96 million. Dimensional Fund Advisors LP increased its holdings by 287,696 shares, an 8.1% rise, ending with 3,856,915 shares valued at $82.50 million. Lastly, Victory Capital Management Inc. grew its stake by 23,653 shares, a 0.6% increase, holding a total of 3,841,933 shares valued at $82.18 million.

Analysts Set New Price Targets

Analysts have maintained their ratings on MD. On May 12, 2026, UBS maintained its 'hold' rating with a price target of $25. Truist Securities also stuck with a 'hold' rating, setting a target of $23 on April 13, 2026. The consensus outlook appears cautious, with analysts holding a 'hold' recommendation and a mean price target around $23 to $25.

Bottom Line

David Haddock's insider purchase of 51,000 shares at MD highlights ongoing interest from company executives. Institutional investors like BlackRock and Vanguard have also been adjusting their positions, signaling varied levels of confidence. Analysts remain cautious, maintaining 'hold' ratings with price targets between $23 and $25. While these insider and institutional activities offer insights, they reflect past actions and may not indicate future performance.